Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706398 | 1.00 | SYK (0.53) | SYKKLK5KLK7TSHRMAPT | |
| SCHEMBL1504055 | 1.00 | SYK (0.53) | SYKKLK5KLK7TSHRMAPT | |
| SCHEMBL27805991 | 0.92 | SYK (0.52) | SYKKLK5KLK7MAPTPPARA | |
| SCHEMBL27805989 | 0.92 | SYK (0.52) | SYKKLK5KLK7MAPTPPARA | |
| SCHEMBL4364181 | 0.89 | SYK (0.54) | SYKKLK5KLK7MAPTPPARA | |
| SCHEMBL207511 | 0.86 | SYK (0.55) | SYKKLK5KLK7TSHRMAPT | |
| SCHEMBL209116 | 0.86 | SYK (0.55) | SYKKLK5KLK7TSHRMAPT | |
| SCHEMBL13473773 | 0.81 | SYK (0.49) | SYKKLK5KLK7TSHRMAPT | |
| SCHEMBL25491606 | 0.79 | KLK7 (0.59) | SYKKLK5KLK7TSHRPPARA | |
| SCHEMBL5419241 | 0.79 | KLK7 (0.59) | SYKKLK5KLK7TSHRPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | SYK 1556/4885KLK5 1230/4885KLK7 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.